|
|
|
| Relationship of RIZ1 and CD133 Expression Levels with Development of Serous Ovarian Cancer |
| LYU Li-hua, WANG Cheng-xiu |
| Department of Gynecology ,Weinan Central Hospital,Weinan Shaanxi 714000 |
|
|
|
|
Abstract 【Objective】 To investigate the expression and clinical significance of retinoblastoma protein-binding zinc finger structure gene (RIZ1) and 5-time transmembrane protein (CD133) in serous ovarian cancer tissues. 【Methods】 We selected 70 cases of ovarian cancer patients (ovarian cancer group) and 70 cases of normal ovarian tissue obtained from surgery of uterine fibroids in our hospital from January 2017 to June 2018 (the control group).Expression levels of RIZ1 protein and CD133 protein in the two groups were detected by immunohistochemical staining and analyzed hierarchically according to histological grade, FIGO stage and lymph node metastasis. 【Results】 The positive expression rates of RIZ1 protein and CD133 protein in ovarian cancer tissues were 32.86%(23/70)and 51.43%(36/70), respectively. The positive expression rates of RIZ1 protein and CD133 protein in the control group were 85.71%(60/70) and 11.43%(8/70), respectively. The difference between the two groups was statistically significant (P<0.05). The difference in positive expression rate of RIZ1 protein in ovarian cancer tissues of patients with different histological differentiation was statistically significant (P<0.05). However, the difference in positive expression rate of RIZ1 protein in ovarian cancer patients with different FIGO stages and lymph node metastasis was not statistically significant (P>0.05). The differences in positive expression rate of CD133 in ovarian cancer tissues of patients with different histological differentiation, different FIGO stages, and whether lymph node metastasis occurred were statistically significant(P<0.05). 【Conclusion】 The expression of RIZ1 protein is down-regulated and the expression of CD133 protein is up-regulated in serous ovarian cancer tissues. These are closely related to the occurrence and development of tumors.
|
|
Received: 07 November 2019
|
|
|
|
|
|
[1] SINGH J, THOTA N, SINGH S, et al. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations[J].Breast Cancer Res Treat,2018,170(1):189-196.
[2] 蒋立艳,楼湘莹,王自能,等. CD133+卵巢癌干细胞样细胞在血管内皮细胞中的分化[J].中国组织工程研究,2015,19(41):6623-6627.
[3] 冯丹,邹娟,方芳. CD_(133)及CD_(44)表达与不同类型上皮性卵巢癌组织[J].中华妇幼临床医学杂志(电子版),2018,14(4):447-452.
[4] 周琦,吴小华,刘继红,等. 卵巢恶性肿瘤诊断与治疗指南(第四版)[J].中国实用妇科与产科杂志,2018,34(7):739-749.
[5] 张金秋,张毅鹏,黄立,等.腹腔灌注顺铂联合深部热疗治疗卵巢癌的疗效及对腹腔积液控制情况的影响[J].癌症进展,2018,16(8):990-993.
[6] 王瑛琨,熊春莲,陈丽丽,等. 叶酸受体α在浆液性卵巢癌患者血清中的表达及其临床意义[J].医学临床研究, 2018, 35(1): 124-125.
[7] 闫真,田晓予,王瑞芳,等. 上皮性卵巢癌中E盒结合锌指蛋白2和转化生长因子β1的表达及其预后的关系[J].国际免疫学杂志,2016,39(3):229-233.
[8] 刘妍,刘颖,俊梅. 卵巢癌患者血清CD133和miR-145的表达与临床病理特征及预后的关系[J].中国妇幼保健,2017,32(14):3155-3158.
[9] 童文先,何安兵,张涛,等. 肿瘤干细胞标记物CD133和CD44在卵巢癌组织的表达及其临床意义[J].中国老年学杂志,2017,37(24):6098-6100.
[10] 张国珍,杨艳萍,周寒丽,等. 抑癌基因RIZ1与妇科恶性肿瘤关系的研究进展[J].现代肿瘤医学,2015,23(15):2213-2215.
[11] 俞岚.上皮性卵巢癌中CD133与EMT相关因子表达的关系[J].南方医科大学学报,2015,35(9):1297-1302. |
|
|
|
2021, Vol. 38 
